Avexa woos investors with late-stage prospects

Australia's Avexa has been wooing investors recently over the prospects of its late-stage HIV therapy, and the added attention has paid off with a spike in its stock price. Avexa shares jumped 23 percent, rising to 19 cents, as it readies a presentation on a Phase III trial of its apricitabine HIV treatment. "We've just been talking to people about that, and that's created some interest within the market," Avexa CEO Julian Chick told Bloomberg. Report

Suggested Articles

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Canadian biotech AbCellera has nabbed a meaty $105 million series B funding round as it looks to boost its antibody work and seek out new potential me

Q32 Bio is working on treatments for autoimmune and inflammatory diseases that improve on systemic approaches.